{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Cancer treatment", "Dual inhibitor", "PI3K/mTOR", "Structural optimization"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "31228810", "DateCompleted": {"Year": "2019", "Month": "10", "Day": "02"}, "DateRevised": {"Year": "2021", "Month": "12", "Day": "04"}, "Article": {"ArticleDate": [{"Year": "2019", "Month": "06", "Day": "13"}], "Language": ["eng"], "ELocationID": ["10.1016/j.ejmech.2019.06.021", "S0223-5234(19)30546-X"], "Journal": {"ISSN": "1768-3254", "JournalIssue": {"Volume": "178", "PubDate": {"Year": "2019", "Month": "Sep", "Day": "15"}}, "Title": "European journal of medicinal chemistry", "ISOAbbreviation": "Eur J Med Chem"}, "ArticleTitle": "Discovery of 4-phenyl-2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as potent and orally active PI3K/mTOR dual inhibitors.", "Pagination": {"StartPage": "667", "EndPage": "686", "MedlinePgn": "667-686"}, "Abstract": {"AbstractText": ["PI3K/Akt/mTOR signaling pathway plays an important role in cancer cell growth and survival. In this study, a new class of molecules with skeleton of 4-phenyl-2H-benzo[b] [1,4]oxazin-3(4H)-one were designed and synthesized targeting this pathway. Bioassays showed that, among all the molecules, 8d-1 was a pan-class I PI3K/mTOR inhibitor with an IC<sub>50</sub> of 0.63\u202fnM against PI3K\u03b1. In a wide panel of protein kinases assays, no off-target interactions of 8d-1 were identified. 8d-1 was orally available, and displayed favorable pharmacokinetic parameters in mice (oral bioavailability of 24.1%). In addition, 8d-1 demonstrated significant efficiency in Hela/A549 tumor xenograft models (TGI of 87.7% at dose of 50\u202fmg/kg in Hela model) without causing significant weight loss and toxicity during 30 days treatment. Based on the bioassays, compound 8d-1 could be used as an anti-cancer drug candidate."], "CopyrightInformation": "Copyright \u00a9 2019. Published by Elsevier Masson SAS."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu, 610041, China."}], "LastName": "Yan", "ForeName": "Guoyi", "Initials": "G"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu, 610041, China."}], "LastName": "Pu", "ForeName": "Chunlan", "Initials": "C"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu, 610041, China."}], "LastName": "Lan", "ForeName": "Suke", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu, 610041, China."}], "LastName": "Zhong", "ForeName": "Xinxin", "Initials": "X"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Engineering Research Center for the Development and Application of Ethnic Medicine and TCM, Ministry of Education & State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550004, Guizhou, China."}], "LastName": "Zhou", "ForeName": "Meng", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Pharmacy, Xinxiang Medical University, Xinxiang, Henan, 453003, China."}], "LastName": "Hou", "ForeName": "Xueyan", "Initials": "X"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu, 610041, China."}], "LastName": "Yang", "ForeName": "Jie", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu, 610041, China."}], "LastName": "Shan", "ForeName": "Huifang", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Sichuan Industrial Institute of Antibiotics, Chengdu University, Chengdu, 610052, China. Electronic address: lifengzhao@scu.edu.cn."}], "LastName": "Zhao", "ForeName": "Lifeng", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu, 610041, China. Electronic address: lirui@scu.edu.cn."}], "LastName": "Li", "ForeName": "Rui", "Initials": "R"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "France", "MedlineTA": "Eur J Med Chem", "NlmUniqueID": "0420510", "ISSNLinking": "0223-5234"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Benzoxazines"}, {"RegistryNumber": "0", "NameOfSubstance": "Phosphoinositide-3 Kinase Inhibitors"}, {"RegistryNumber": "0", "NameOfSubstance": "Protein Kinase Inhibitors"}, {"RegistryNumber": "EC 2.7.1.1", "NameOfSubstance": "MTOR protein, human"}, {"RegistryNumber": "EC 2.7.11.1", "NameOfSubstance": "TOR Serine-Threonine Kinases"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Administration, Oral"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["administration & dosage", "chemistry", "pharmacology"], "DescriptorName": "Antineoplastic Agents"}, {"QualifierName": ["administration & dosage", "chemistry", "pharmacology"], "DescriptorName": "Benzoxazines"}, {"QualifierName": [], "DescriptorName": "Cell Line, Tumor"}, {"QualifierName": ["drug effects"], "DescriptorName": "Cell Proliferation"}, {"QualifierName": ["drug effects"], "DescriptorName": "Cell Survival"}, {"QualifierName": [], "DescriptorName": "Dose-Response Relationship, Drug"}, {"QualifierName": [], "DescriptorName": "Drug Discovery"}, {"QualifierName": [], "DescriptorName": "Drug Screening Assays, Antitumor"}, {"QualifierName": [], "DescriptorName": "HeLa Cells"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": [], "DescriptorName": "Mice"}, {"QualifierName": [], "DescriptorName": "Mice, Inbred BALB C"}, {"QualifierName": [], "DescriptorName": "Mice, Nude"}, {"QualifierName": [], "DescriptorName": "Molecular Structure"}, {"QualifierName": ["drug therapy", "metabolism", "pathology"], "DescriptorName": "Neoplasms, Experimental"}, {"QualifierName": ["metabolism"], "DescriptorName": "Phosphatidylinositol 3-Kinases"}, {"QualifierName": [], "DescriptorName": "Phosphoinositide-3 Kinase Inhibitors"}, {"QualifierName": ["administration & dosage", "chemistry", "pharmacology"], "DescriptorName": "Protein Kinase Inhibitors"}, {"QualifierName": [], "DescriptorName": "Rats"}, {"QualifierName": [], "DescriptorName": "Rats, Sprague-Dawley"}, {"QualifierName": [], "DescriptorName": "Structure-Activity Relationship"}, {"QualifierName": ["antagonists & inhibitors", "metabolism"], "DescriptorName": "TOR Serine-Threonine Kinases"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2019", "Month": "4", "Day": "11"}, {"Year": "2019", "Month": "6", "Day": "5"}, {"Year": "2019", "Month": "6", "Day": "7"}, {"Year": "2019", "Month": "6", "Day": "23", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "10", "Day": "3", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "6", "Day": "23", "Hour": "6", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["31228810", "10.1016/j.ejmech.2019.06.021", "S0223-5234(19)30546-X"]}}]}